Intellia Therapeutics Inc to Discuss Interim Clinical Data from NTLA-2001 Phase 1 Study Transcript
Good morning, and welcome to Intellia's Therapeutics Investor event to discuss the updated interim clinical data from the Phase I study of NTLA-2001. My name is Jason, and I will be your conference operator today. Please be advised that this call is being recorded at the company's request. (Operator Instructions) I will now turn the conference over to Ian Karp, Senior Vice President of Investor Relations and Corporate Communications at Intellia. Please proceed.
Thank you, operator, and good morning, everyone. I'm pleased to welcome you to Intellia's investor event featuring updated interim data from the Phase I clinical trial of NTLA-2001. Earlier today, Intellia issued a press release detailing these results. This release, along with the accompanying presentation can be found on the Investors & Media section of Intellia's website at intelliatx.com.
As a reminder, this call is being broadcast live and a replay of the event will be archived on the company's website. At
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |